Accurate projection of the costs of cancer care in the United States on a regular basis is
critically important for decision makers to understand the economic impact of cancer and to
develop and assess cost containment policies and interventions. We propose to systematically
develop new methodology for cost estimation and projection that addresses analytical
challenges in the phase-of-care costing method, which was developed more than two decades
ago and has since been adopted by the National Cancer Institute in its periodic cost reporting.
Our methodology includes new methods to (a) model the longitudinal cost trajectories without
artificial partitioning of initial, continuing, and terminal care phases, (b) identify more comparable
matched control cohort in the estimation of net cost attributable to cancer, (c) to extrapolate the
cost trajectories estimated from SEER-Medicare database to the general United States
population and validate the extrapolation algorithm for the purpose of projecting national cancer
care costs. We will apply the proposed methods to SEER-Medicare data to project the costs of
the top five most costly cancers (breast, colorectal, lung, prostate, and lymphoma), plus
leukemia, in the United States between 2020 and 2030. User-friendly software will be developed
and disseminated for routine use.
If you are accessing this page during weekend or evening hours, the database may currently be offline for maintenance and should operational within a few hours. Otherwise, we have been notified of this error and will be addressing it immediately.
Please contact us
if this error persists.
We apologize for the inconvenience.
- The DCCPS Team.